Dermatology Times January 2026 Recap

Clearances, Approvals, Updates, and Recommendations

First Patient Dosed in Phase 3 VP-102 Common Warts Program

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.

Legacy Healthcare Receives FDA Clearance to Advance Cinainu to Phase 3 AA Clinical Trials

Legacy Healthcare has advanced Cinainu into a phase 3 study for alopecia areata, offering hope for effective, safe treatment without immunosuppression.

FDA Feedback Supports BLA Pathway for Sonelokimab in HS

MoonLake Immunotherapeutics shares promising updates on sonelokimab's efficacy for hidradenitis suppurativa.

Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS

Navigator Medicines advances NAV-240 and NAV-242, targeting dual inflammation pathways for hidradenitis suppurativa in upcoming clinical trials.

Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT

Alpha Tau Medical advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC), offering a novel, localized treatment option with minimal toxicity.

Lebrikizumab Enters Late-Stage Testing for Nummular Eczema

Almirall initiates a pivotal phase 3 trial for lebrikizumab, targeting nummular eczema and aiming to enhance treatment options for this challenging condition.

Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia

Quoin Pharmaceuticals seeks Breakthrough Medicine Designation for QRX003, aiming to provide the first treatment for Netherton Syndrome in Saudi Arabia.

Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus

DELTA CARE 1 is the first phase 3 investigation of a pan–Janus kinase inhibitor specifically for lichen sclerosus.

FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus

The FDA’s decision was based on litifilimab’s phase 2 skin disease activity data.

Big Studies and Big Data

Phase 3 Data Support Oral TYK2 Inhibitor Envudeucitinib for Psoriasis

Envudeucitinib shows promising results as a new oral therapy for psoriasis, achieving high skin clearance rates and rapid symptom improvement in clinical trials.

Phase 1b Asthma Data Highlight Durable IL-13 Suppression With Zumilokibart

Apogee Therapeutics reveals promising phase 1b trial results for zumilokibart, highlighting its potential as a durable treatment for atopic dermatitis.

First-in-Class FcRn Inhibitor Nipocalimab Meets Primary End Point in Phase 2b Study for Active SLE

Johnson & Johnson's nipocalimab shows promise in reducing systemic lupus erythematosus activity, paving the way for a phase 3 development program.

Jasper Therapeutics Announces Positive Updated Phase 1b/2a Data for Briquilimab in CSU

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Eli Lilly Trial Shows Superior Outcomes With Ixekizumab and Tirzepatide in Patients With PsA and Obesity

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD

Phase 1 cohort 4 data show soquelitinib demonstrated sustained clinical activity through 8 weeks, including in patients with prior systemic therapy exposure.

Amlitelimab Demonstrates Efficacy With Every-12-Weeks Dosing in AD Trials

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.

Galderma Presents Phase 3 Relfydess Data and Dysport Innovations at TOXINS 2026

Galderma showcased relabotulinumtoxinA and abobotulinumtoxinA at TOXINS 2026, highlighting innovative injectables with sustained results and high patient satisfaction.

Market, Pharma, and Specialty News

Dermatology Market Update 2026: Second Bites, Regulatory Headwinds, and the Flight Toward Scale

Dermatology investment trends shift as private equity re-enters the market, focusing on practices with strong infrastructure and clinical excellence.

Interim Analysis Leads to Early Termination of DUPLEX-AD Study

Johnson & Johnson reveals JNJ-95475939's early termination due to insufficient efficacy in treating moderate to severe atopic dermatitis.

Recludix Pharma’s REX-8756 for Type 2 Inflammatory Diseases Enters First Human Trials

Recludix Pharma has initiated clinical trials for REX-8756, a promising oral STAT6 inhibitor targeting inflammatory diseases, marking a significant milestone in treatment innovation.

Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications

Connect Biopharma reveals innovative data on rademikibart's mechanism of action, highlighting its potential impact on atopic dermatitis and future clinical priorities.

NPF Position Statement Aligns Severity Classification With Treatment Needs

The National Psoriasis Foundation (NPF) redefines psoriasis severity, emphasizing disease impact over extent, enhancing treatment access, and aligning clinical practice with patient needs.

Sun Pharma’s Cosibelimab-ipdl (UNLOXCYT) Enters US Market for Advanced CSCC

Sun Pharma has launched cosibelimab-ipdl for advanced cutaneous squamous cell carcinoma, offering new hope for patients with limited treatment options.

Obagi Medical and Alpha Aesthetic Partners Announce Collaboration on ALOHA Program

Obagi and Alpha Aesthetic Partners will collaborate on the ALOHA Program, enhancing real-world evidence for the innovative saypha MagIQ hyaluronic acid filler.

Strides for Skin Health Equity

The Evolving Evidence Base in Hyperhidrosis Care

Explore the latest insights on hyperhidrosis, its impact on quality of life, and advancements in effective treatment options for this often-overlooked condition.

Patients Over 60 Face Increasing Melanoma Risk as Global Burden Shifts

Elderly populations are facing rising cutaneous malignant melanoma incidence and mortality, highlighting urgent needs for targeted prevention and early detection strategies in skin cancer care.

New Study Reveals High Rates of Addiction Among Patients with Psoriasis and Other Conditions

Chronic skin diseases like psoriasis and AD are linked to high smoking and other addiction rates, highlighting the need for integrated psychosocial support.

National Survey Highlights Unmet Needs and TCS Concerns in Chronic Inflammatory Skin Diseases

The survey revealed significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive, long-term treatment strategies.

Clinicians See Intersection of Weight Loss and Facial Aging

Public interest in GLP-1 weight loss medications surges, revealing concerns about aesthetic effects like "Ozempic face" and prompting new treatment strategies.

Q&A with Karen McGuire, PhD: How TolaSure Aims to Redefine the Standard of Care for EBS

Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.